Acetylcysteine - AstraZeneca

Drug Profile

Acetylcysteine - AstraZeneca

Alternative Names: Mucomyst; N-acetylcysteine; N-Acetylcysteine - AstraZeneca; NAC; NAC - AstraZeneca

Latest Information Update: 05 Aug 2004

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Class Antibronchitics; Antidotes; Expectorants; Reducing agents; Small molecules; Sulfur amino acids
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Bronchiectasis; Chronic obstructive pulmonary disease; Cystic fibrosis; Dry eyes; Poisoning

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 31 Dec 2002 Launched for Bronchiectasis in Australia (Inhalation)
  • 31 Dec 2002 Launched for Chronic obstructive pulmonary disease in Austria (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top